Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes

Journal of Proteomics
Akshada GajbhiyeSrikanth Rapole

Abstract

Being molecularly heterogeneous, breast cancer tends to be a complicated oncological disease with high incidence rates throughout the world. The primary aim of this study was to identify the set of serum proteins with discriminatory capabilities towards the four major subtypes of breast cancer. We employed multipronged quantitative proteomic approaches like 2D-DIGE, iTRAQ and SWATH-MS and identified 307 differentially regulated proteins. Luminal A subtype consisted of 24, Luminal B subtype 38, HER2 Enriched subtype 17 and Triple negative breast cancer subtype 10 differentially regulated subtype specific proteins. These specific proteins were further subjected to bioinformatic tools which revealed the involvement in platelet degranulation, fibrinolysis, lipid metabolism, immune response, complement activation, blood coagulation, glycolysis and cancer signaling pathways in the subtypes of the breast cancer. The significant discrimination efficiency of the models generated through multivariate statistical analysis was decent to distinguish each of the four subtypes from controls. Further, some of the statistically significant differentially regulated proteins were verified and validated by immunoblotting and mass spectrometry base...Continue Reading

References

Dec 29, 1999·Nature Medicine
Aug 30, 2000·Nature·C M PerouD Botstein
May 3, 2002·British Journal of Cancer·Edward R SauterG C Du Bois
Apr 3, 2003·Nature Reviews. Cancer·Ruth EtzioniLeland Hartwell
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jinong LiDaniel W Chan
May 17, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Susan E PoriesMarsha A Moses
Jan 10, 2009·Nature Protocols·Da Wei HuangRichard A Lempicki
Sep 28, 2010·Molecular Cancer Research : MCR·Martin J RutkowskiAndrew T Parsa
Jan 1, 2009·Human Genomics and Proteomics : HGP·Kondethimmanahalli Chandramouli, Pei-Yuan Qian
Dec 8, 2010·Proteomics. Clinical Applications·Harikrishna NakshatriMu Wang
Jan 25, 2011·Nature Reviews. Cancer·Laurie J Gay, Brunhilde Felding-Habermann
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 20, 2012·Clinical Biochemistry·V M GarrisiA Paradiso
Aug 3, 2013·Breast Cancer Research : BCR·Inder LalChris E Holmes
Nov 10, 2013·Disease Models & Mechanisms·Franziska BaenkeAlmut Schulze
Nov 26, 2013·Advances in Experimental Medicine and Biology·Ruben PioJohn D Lambris
Mar 13, 2014·American Journal of Clinical Pathology·Robert SchmadekaMeenakshi Singh
Aug 13, 2014·World Journal of Clinical Oncology·Ozlem Yersal, Sabri Barutca
Sep 16, 2014·Journal of Proteome Research·Carolina PanisEliana Abdelhay
Jul 17, 2015·JAMA Oncology·UNKNOWN Global Burden of Disease Cancer CollaborationMohsen Naghavi
Nov 4, 2015·Nucleic Acids Research·Juan Antonio VizcaínoHenning Hermjakob
Dec 19, 2015·BMC Medical Genomics·Adam Handen, Madhavi K Ganapathiraju
Jan 5, 2016·Nature Communications·Stefka TyanovaTamar Geiger
Jun 3, 2016·Nature·Philipp MertinsUNKNOWN NCI CPTAC

❮ Previous
Next ❯

Citations

Jan 11, 2020·Frontiers in Microbiology·Lifen HanHanhui Ye
Jun 25, 2020·Expert Review of Proteomics·Khushman TaunkSrikanth Rapole
Nov 14, 2020·International Journal of Molecular Sciences·María Del Pilar Chantada-VázquezCristina Núñez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.